SEOUL, South Korea--(BUSINESS WIRE)--Seoul National University Hospital (SNUH) recently announced that it has successfully implemented the interface of the clinical and genomic data in accordance with the Korean medical system and officially launched the Syapse Precision Medicine (PM) platform for the first time in both Korea and APAC. The contract for the adoption of Syapse platform was signed back in early 2018.
Based on the integrated clinical/genomic data, it is now possible to provide a software platform that provides patient-oriented and cost-effective cancer treatment for domestic patients for the first time, maximizing utilization of the genomic data.
Syapse is a provider of health care solutions based in San Francisco, U.S. The company specializes in helping oncologists provide cancer patients through improved treatment with optimized therapies. With their mission, ‘To provide the best treatment for all cancer patients through Precision Medicine (PM)’ Syapse has implemented PM platform at 300+ hospitals located in 25 states across the U.S. The hospital has established PM platform to provide fully optimized cancer treatment for approximately 1 million people, 10% of the total cancer patient population in the U.S.
In Korea, Megazone, the country's largest AWS partner and cloud specialized company signed an exclusive partnership agreement with Syapse earlier this year, to assist with the adoption, deployment and operation of the PM solutions.
Megazone is the first cloud MSP to achieve a revenue of 110 million dollars in the Korean market last year and it has already achieved a sales revenue of more than 112 million dollars in the H1 2018. In 2012, Megazone signed the partnership with Amazon Web Services for the first time in Korea and was selected as Premier Consulting Partner, the highest level for AWS partner in 2015. Megazone is the first and only one to have acquired ISMS, Information Security Management System certification. Megazone is currently offering ‘Cloud One-Stop’ service across the full life cycle based on the holistic methodology, including cloud adoption, implementation, deployment, operation, security/back-up, 24/7 support, managed services and optimization, to more than 800 customers.
The newly-launched Syapse platform, made available through the cooperation of the two organizations, has significance in that it’s the first case ever in APAC.
Meanwhile, SNUH successfully held the Syapse Opening Symposium at its facility on July 13th in accordance with the launch of the platform.
The symposium, with the theme of "Present and Future of Korea's Precision Medicine Platform", was held on the successful adoption experience and developments of the Syapse platform, the first cancer treatment medical platform in Korea and APAC, with more than 300 experts attending.
In the first session, introduction on SNUH and Syapse was made, along with a case study in the U.S. presented. Also, the professors from the Information Technology team, Precision Medicine center, and other medical departments participated in discussing the six-month adoption journey of the Syapse platform as well as the trends and future. The second half of the event was on the examination of the present and future of the Korean Precision Medicine platform through lectures and panel discussions among internal and external experts.
“Syapse is a powerful platform that could help us make effective cancer treatment decisions using genetic analysis technology. With this, SNUH will present a new standard in the treatment of evidence-based precision cancer and oncology” said Kyung Hwan Kim, the head of SNUH Information Team.
“I would like to congratulate SNUH for the official launch of the first cancer Precision Medicine platform service in Korea. As a cutting-edge Precision Medicine solution proven in the global market, Syapse will help SNUH medical staff make more effective decisions in cancer treatment. I believe that this will serve as a stepping stone for development of the Korean medical community and the reinforcement of the medical treatment competence of cancer patients.” said Max Lee, CSO of Megazone Corporation.